Ryan Murr > Gibson, Dunn & Crutcher LLP > San Francisco, United States > Lawyer Profile

Gibson, Dunn & Crutcher LLP
555 Mission Street, Suite 3000
San Francisco, CA 94105-0921
United States

Work Department

Life Sciences, Corporate, Capital Markets


Co-chair, global life sciences practice, Ryan focuses on representing operating companies and investors in the biotechnology, pharmaceutical, diagnostics and medical device industries in connection with securities offerings, corporate governance matters and business combination transactions. He serves as principal outside counsel for publicly-traded companies and venture-backed companies, advising management teams and boards of directors on general corporate matters, securities offerings, SEC reporting, corporate governance, licensing transactions and mergers & acquisitions. He also advises investment funds (private equity funds, hedge funds, venture funds and royalty buyout funds) in connection with investments in life sciences companies and assets.


For more information, please visit https://www.gibsondunn.com/lawyer/murr-ryan-a/.

Lawyer Rankings

United States > Industry focus > Healthcare: life sciences

IP litigation is at the core of Gibson, Dunn & Crutcher LLP‘s life sciences practice, with the team representing a number of biotech companies. The team is able to act on smaller civil infringements and appeal cases alike, as well as representing up to Supreme Court level Most notably, the team defended a patent challenge to Novartis’ MS medication Gilenya. In addition to IP, the team offers strong transactional support to large scale clients and further support on FDA investigations and compliance matters. Jane Love and Ryan Murr co-lead the team from New York and San Francisco respectively.

United States > M&A/corporate and commercial > Venture capital and emerging companies

Gibson, Dunn & Crutcher LLP has an impressive venture capital and emerging companies practice working out of its California offices. The firm is less focused on advising multiple early stage companies, instead taking a more selective approach to mid-to-late stage investments. This includes domestic and cross-border transactions, where it represents investors and issuers on major financings, M&As and capital markets exits. The versatile group has expertise across a range of industries, including pharmaceutical, media, entertainment, technology, telecoms and gaming, and has recently been busy in growing niches such as ad-tech, and social and mobile gaming. Key partners include Ryan Murr, who co-heads the firm’s San Francisco office, and fellow San Francisco partner Stewart McDowell, who co-chairs the firm’s capital markets practice group.